State-Transition Modeling: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force–3

GRADE guidelines: 3. Rating the quality of evidence

Balshem, H., Helfand, M., Schünemann, H. J., Oxman, A. D., Kunz, R., Brozek, J., Vist, G. E., Falck-Ytter, Y., Meerpohl, J., & Norris, S. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.07.015 · Cited by 8,285

Markov Decision Processes

Puterman, M. L. (1994) · Wiley series in probability and statistics · doi:10.1002/9780470316887 · Cited by 6,057

GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology

Guyatt, G. H., Oxman, A. D., Schünemann, H. J., Tugwell, P., & Knottnerus, A. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.09.011 · Cited by 3,094

Markov Models in Medical Decision Making: A Practical Guide

Sonnenberg, F. A., & Beck, J. R. (1993) · Medical Decision Making · doi:10.1177/0272989x9301300409 · Cited by 2,419

The Markov process in medical prognosis

Beck, J. R., & Pauker, S. G. (1983) · Medical Decision Making · doi:10.1177/0272989x8300300403 · Cited by 957

Model Parameter Estimation and Uncertainty Analysis: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group–6

Briggs, A. H., Weinstein, M. C., Fenwick, E. A. L., Karnon, J., Sculpher, M. J., & Paltiel, A. D. (2012) · Medical Decision Making · doi:10.1177/0272989x12458348 · Cited by 887

Model Transparency and Validation

Eddy, D. M., Hollingworth, W., Jaime, J., Tsevat, J., McDonald, K. M., & Wong, J. B. (2012) · Medical Decision Making · doi:10.1177/0272989x12454579 · Cited by 803

Model Parameter Estimation and Uncertainty: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-6

Briggs, A. H., Weinstein, M. C., Fenwick, E. A. L., Karnon, J., Sculpher, M. J., & Paltiel, A. D. (2012) · Value in Health · doi:10.1016/j.jval.2012.04.014 · Cited by 711

A model to estimate the lifetime health outcomes of patients with Type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68)

Clarke, P. M., Gray, A. M., Briggs, A., Farmer, A. J., Fenn, P., Stevens, R. J., Matthews, D. R., Stratton, I. M., Holman, R. R., & on behalf of the UK Prospective Diabetes Study (UKPDS) Group (2004) · Diabetologia · doi:10.1007/s00125-004-1527-z · Cited by 615

Cost-Effectiveness of Screening for HIV in the Era of Highly Active Antiretroviral Therapy

Sanders, G. D., Bayoumi, A. M., H, V. S. M. P., Bilir, S. P., Neukermans, C. P., Rydzak, C. E., Douglass, L. R., Lazzeroni, L. C., Holodniy, M., & Owens, D. K. (2005) · New England Journal of Medicine · doi:10.1056/nejmsa042657 · Cited by 603

Familial hypercholesterolemia: A systematic review of modeling studies on screening interventions

Jahn, B., Santamaria, J., Dieplinger, H., Binder, C. J., Ebenbichler, C. F., Scholl‐Bürgi, S., Conrads‐Frank, A., Rochau, U., Kühne, F., Stojkov, I., et al. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.06.1011 · Cited by 19

Verification of Decision-Analytic Models for Health Economic Evaluations: An Overview

Dasbach, E. J., & Elbasha, E. H. (2017) · PharmacoEconomics · doi:10.1007/s40273-017-0508-2 · Cited by 19

Simple but not simpler: a systematic review of Markov models for economic evaluation of cervical cancer screening

Viscondi, J. Y. K., Faustino, C. G., Campolina, A. G., Itria, A., & de Soárez, P. C. (2018) · Clinics · doi:10.6061/clinics/2018/e385 · Cited by 19

Cost-effectiveness of internet-supported cognitive behavioral therapy for university students with anxiety symptoms: A Markov-model analysis

You, J. H. S., Luk, S. W. C., Chow, D. Y. W., Jiang, X., Mak, A. D. P., & Mak, W. W. S. (2022) · PLoS ONE · doi:10.1371/journal.pone.0268061 · Cited by 18

Endoscopic polypectomy in the clinic: a pilot cost‐effectiveness analysis

Rudmik, L. R., Smith, K. A., & Kilty, S. (2015) · Clinical Otolaryngology · doi:10.1111/coa.12473 · Cited by 18

Intermittent pneumatic compression is a cost-effective method of orthopedic postsurgical venous thromboembolism prophylaxis

Saunders, R., Comerota, A. J., Ozols, A., Torres, R. T., & Ho, K. M. (2018) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s157306 · Cited by 18

Modeling Retinal Ganglion Cell Dysfunction in Optic Neuropathies

Porciatti, V., & Chou, T.-H. (2021) · Cells · doi:10.3390/cells10061398 · Cited by 18

An economic analysis of high-dose imatinib, dasatinib, and nilotinib for imatinib-resistant chronic phase chronic myeloid leukemia in China

Wu, B., Liu, M., Li, T., Lin, H., & Zhong, H. (2017) · Medicine · doi:10.1097/md.0000000000007445 · Cited by 18

Is risk-stratified breast cancer screening economically efficient in Germany?

Arnold, M., Pfeifer, K., & Quante, A. S. (2019) · PLoS ONE · doi:10.1371/journal.pone.0217213 · Cited by 17

Nutrition and public health economic evaluations under the lenses of post normal science

Piano, S. L., & Robinson, M. (2019) · Futures · doi:10.1016/j.futures.2019.06.008 · Cited by 17

Good Practices for Health Technology Assessment Guideline Development: A Report of the Health Technology Assessment International, HTAsiaLink, and ISPOR Special Task Force

Botwright, S., Sittimart, M., Chavarina, K. K., Bayani, D. B., Merlin, T., Surgey, G., Suharlim, C., Espinoza, M., Culyer, A. J., Oortwijn, W., et al. (2024) · International Journal of Technology Assessment in Health Care · doi:10.1017/s0266462324004719 · Cited by 16

Causal evidence in health decision making: methodological approaches of causal inference and health decision science

Kühne, F., Schomaker, M., Stojkov, I., Jahn, B., Conrads‐Frank, A., Siebert, S., Sroczynski, G., Puntscher, S., Schmid, D., Schnell‐Inderst, P., et al. (2022) · PubMed Central · doi:10.3205/000314 · Cited by 17

Lives Saved by Expanding HIV Treatment Availability in Resource-Limited Settings

Kimmel, A. D., Charles, M., Deschamps, M.-M., Sévère, P., Edwards, A. M., Johnson, W. D., Fitzgerald, D. W., Pape, J. W., & Schackman, B. R. (2013) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e3182918875 · Cited by 16

Appropriate Evidence Sources for Populating Decision Analytic Models within Health Technology Assessment (HTA)

Zechmeister-Koss, I., Schnell-Inderst, P., & Zauner, G. (2014) · Medical decision making · doi:10.1177/0272989x13509406 · Cited by 9

Incremental costs and cost-effectiveness of intensive treatment in individuals with type 2 diabetes detected by screening in the ADDITION-UK trial: An update with empirical trial-based cost data

Laxy, M., Wilson, E., Boothby, C. E., & Griffin, S. (2017) · Value in Health · doi:10.1016/j.jval.2017.05.018 · Cited by 12

Planning the home and facility-based care dynamics using the multiple decrement approach: The case study for Slovenia

Rogelj, V., & Bogataj, D. (2018) · IFAC-PapersOnLine · doi:10.1016/j.ifacol.2018.08.476 · Cited by 16

Health variations among breast-cancer patients from different disease states: evidence from China

Yang, Q., Yu, X., & Zhang, W. (2020) · BMC Health Services Research · doi:10.1186/s12913-020-05872-5 · Cited by 16

Cost Effectiveness of Ofatumumab Plus Chlorambucil in First-Line Chronic Lymphocytic Leukaemia in Canada

Herring, W. L., Pearson, I. V., Purser, M. F., Nakhai-Pour, H. R., Haiderali, A., Wolowacz, S. E., & Jayasundara, K. (2015) · PharmacoEconomics · doi:10.1007/s40273-015-0332-5 · Cited by 16

Cost–effectiveness analysis of simeprevir with daclatasvir for non-cirrhotic genotype-1b-naïve patients plus chronic hepatitis C

Gimeno‐Ballester, V., Mar, J., & Miguel, R. S. (2015) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1586/14737167.2015.1081061 · Cited by 15

Decision-analytic modeling studies: An overview for clinicians using multiple myeloma as an example

Rochau, U., Jahn, B., Qerimi, V., Burger, E. A., Kurzthaler, C., Kluibenschaedl, M., Willenbacher, E., Gastl, G. A., Willenbacher, W., & Siebert, U. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2014.12.017 · Cited by 15

Cost-effectiveness of superabsorbent wound dressing versus standard of care in patients with moderate-to-highly exuding leg ulcers

Veličković, V. M., Chadwick, P., Rippon, M. G., Ilić, I., McGlone, E. R., Gebreslassie, M., Csernus, M., Streit, I., Bordeanu, A., Kaspar, D., et al. (2020) · Journal of Wound Care · doi:10.12968/jowc.2020.29.4.235 · Cited by 15

Transoral incisionless fundoplication is cost-effective for treatment of gastroesophageal reflux disease

McCarty, T. R., Jirapinyo, P., James, L. P., Gupta, S., Chan, W. W., & Thompson, C. C. (2022) · Endoscopy International Open · doi:10.1055/a-1783-9378 · Cited by 15

Good Practices for Health Technology Assessment Guideline Development: A Report of the Health Technology Assessment International, HTAsiaLink, and ISPOR Special Task Force

Botwright, S., Sittimart, M., Chavarina, K. K., Bayani, D. B., Merlin, T., Surgey, G., Suharlim, C., Espinoza, M., Culyer, A. J., Oortwijn, W., et al. (2025) · Value in Health · doi:10.1016/j.jval.2024.09.001 · Cited by 21

Cost‐effectiveness analysis of superabsorbent wound dressings in patients with moderate‐to‐highly exuding leg ulcers in Germany

Veličković, V. M., Szilcz, M., Milošević, Z. G., Godfrey, T., & Siebert, U. (2021) · International Wound Journal · doi:10.1111/iwj.13645 · Cited by 15

2025 AHA/ACC Statement on Cost/Value Methodology in Clinical Practice Guidelines (Update From 2014 Statement)

Kazi, D. S., Abdullah, A. R., Arnold, S. V., Basu, A., Bellows, B. K., Breathett, K., Chew, D. S., Cohen, D. J., DeJong, C., Heidenreich, P. A., et al. (2026) · JACC · doi:10.1016/j.jacc.2025.05.009 · Cited by 14

Cost-effectiveness analysis of therapeutic options for chronic hepatitis C genotype 3 infected patients

Gimeno‐Ballester, V., Mar, J., O’Leary, A. C., Adams, R., & Miguel, R. S. (2016) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2016.1222271 · Cited by 14

One in three adenomas could be missed by white-light colonoscopy – findings from a systematic review and meta-analysis

Jahn, B., Bundo, M., Arvandi, M., Schaffner, M., Todorović, J., Sroczynski, G., Knudsen, A. B., Fischer, T., Schiller-Fruehwirth, I., Öfner, D., et al. (2025) · BMC Gastroenterology · doi:10.1186/s12876-025-03679-4 · Cited by 18

Cost-effectiveness of ocriplasmin for the treatment of vitreomacular traction and macular hole

Bennison, C., Stephens, S., Lescrauwaet, B., van Hout, B., & Jackson, T. L. (2016) · Journal of Market Access & Health Policy · doi:10.3402/jmahp.v4.31472 · Cited by 14

Analyzing the concept of spillover effects for expanded inclusion in health economics research

Muir, K. J., & Keim‐Malpass, J. (2020) · Journal of Comparative Effectiveness Research · doi:10.2217/cer-2020-0051 · Cited by 14

Field Trauma Triage among Older Adults: A Cost-Effectiveness Analysis

Maughan, B. C., Lin, A., Caughey, A. B., Bulger, E. M., McConnell, K. J., Malveau, S., Griffiths, D., & Newgard, C. D. (2022) · Journal of the American College of Surgeons · doi:10.1097/xcs.0000000000000025 · Cited by 14

Modeling the Impact of Retention Interventions on Mother-to-Child Transmission of HIV: Results From INSPIRE Studies in Malawi, Nigeria, and Zimbabwe

McCarthy, E. A., Joseph, J. T., Foster, G., Mangwiro, A., Mwapasa, V., Oyeledun, B., Phiri, S., Sam-Agudu, N. A., Essajee, S. M., & on behalf of the INSPIRE Team (2017) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000001364 · Cited by 14

Cost-effectiveness of osimertinib versus standard EGFR-TKI as first-line treatment for locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer in Australia

Khoo, T., & Gao, L. (2020) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2021.1847648 · Cited by 14

Minimal Residual Disease Evaluation in Childhood Acute Lymphoblastic Leukemia: An Economic Analysis.

(2016) · PubMed Central · Cited by 14

A Decision-Analytic Model to Assess the Cost-Effectiveness of Etelcalcetide vs. Cinacalcet

Stollenwerk, B., Iannazzo, S., Akehurst, R. L., ADENA, M. A., Briggs, A. H., Dehmel, B., Parfrey, P. S., & Belozeroff, V. (2018) · PharmacoEconomics · doi:10.1007/s40273-017-0605-2 · Cited by 13

Congenital heart defect repair with ADAPT tissue engineered pericardium scaffold: An early-stage health economic model

Veličković, V. M., Borisenko, O., Svensson, M., Spelman, T. D., & Siebert, U. (2018) · PLoS ONE · doi:10.1371/journal.pone.0204643 · Cited by 13

Benefit-Risk Assessment of Vaccines. Part II: Proposal Towards Consolidated Standards of Reporting Quantitative Benefit-Risk Models Applied to Vaccines (BRIVAC)

Arlégui, H., Bollaerts, K., Bauchau, V., Nachbaur, G., Bégaud, B., & Praet, N. (2020) · Drug Safety · doi:10.1007/s40264-020-00982-9 · Cited by 13

Systematic review of reporting quality of economic evaluations in plastic surgery based on the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement

Miroshnychenko, A., Uhlman, K., Malone, J. L., Waltho, D., & Thoma, A. (2021) · Journal of Plastic Reconstructive & Aesthetic Surgery · doi:10.1016/j.bjps.2021.05.017 · Cited by 13

Mental health systems modelling for evidence-informed service reform in Australia

Whiteford, H., Bagheri, N., Diminic, S., Enticott, J., Gao, C. X., Hamilton, M. P., Hickie, I. B., Le, L. K., Lee, Y. Y., Long, K. M., et al. (2023) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/00048674231172113 · Cited by 13

Lessons Learned from a Cross-Model Validation between a Discrete Event Simulation Model and a Cohort State-Transition Model for Personalized Breast Cancer Treatment

Jahn, B., Rochau, U., Kurzthaler, C., Paulden, M., Kluibenschaedl, M., Arvandi, M., Kühne, F., Goehler, A., Krahn, M. D., & Siebert, U. (2015) · Medical Decision Making · doi:10.1177/0272989x15604158 · Cited by 13

2. How is the economic assessment of vaccines performed today?

Standaert, B., & Rappuoli, R. (2017) · Journal of Market Access & Health Policy · doi:10.1080/20016689.2017.1335163 · Cited by 13

The cost-effectiveness of semaglutide in reducing cardiovascular risk among people with overweight and obesity and existing cardiovascular disease, but without diabetes

Zomer, E., Zhou, J., Nelson, A. J., Sumithran, P., Nanayakkara, S., Ball, J., Kaye, D. M., Liew, D., Nicholls, S. J., Stub, D. A., et al. (2024) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcae063 · Cited by 12

Economic evaluation of vaccines: specificities and future challenges illustrated by recent European examples

Postma, M. J., Westra, T. A., Quilici, S., & Largeron, N. (2013) · Expert Review of Vaccines · doi:10.1586/erv.13.36 · Cited by 12

The ONCOTYROL Prostate Cancer Outcome and Policy Model

Mühlberger, N., Kurzthaler, C., Iskandar, R., Krahn, M. D., Bremner, K. E., Oberaigner, W., Klocker, H., Horninger, W., Conrads‐Frank, A., Sroczynski, G., et al. (2015) · Medical Decision Making · doi:10.1177/0272989x15585114 · Cited by 12

Benefits and harms of prostate cancer screening – predictions of the ONCOTYROL prostate cancer outcome and policy model

Mühlberger, N., Boskovic, K., Krahn, M. D., Bremner, K. E., Oberaigner, W., Klocker, H., Horninger, W., Sroczynski, G., & Siebert, U. (2017) · BMC Public Health · doi:10.1186/s12889-017-4439-9 · Cited by 12

The effect of model selection on cost-effectiveness research: a comparison of kidney function-based microsimulation and disease grade-based microsimulation in chronic kidney disease modeling

Hiragi, S., Tamura, H., Goto, R., & Kuroda, T. (2018) · BMC Medical Informatics and Decision Making · doi:10.1186/s12911-018-0678-7 · Cited by 12

A Promising Approach to Optimizing Sequential Treatment Decisions for Depression: Markov Decision Process

Li, F., Jörg, F., Li, X., & Feenstra, T. (2022) · PharmacoEconomics · doi:10.1007/s40273-022-01185-z · Cited by 12

Cost-Effectiveness Analysis of an Adherence-Promotion Intervention for Children With Leukemia: A Markov Model-Based Simulation

McGrady, M. E., Eckman, M. H., O'Brien, M. M., & Pai, A. L. H. (2018) · Journal of Pediatric Psychology · doi:10.1093/jpepsy/jsy022 · Cited by 12

Benefits and Harms of a Prevention Program for Iodine Deficiency Disorders: Predictions of the Decision-Analytic EUthyroid Model

Schaffner, M., Mühlberger, N., Conrads‐Frank, A., Qerimi, V., Sroczynski, G., Koukkou, E. G., Thuesen, B. H., Völzke, H., Oberaigner, W., Siebert, U., et al. (2020) · Thyroid · doi:10.1089/thy.2020.0062 · Cited by 12

Markov Influence Diagrams

Díez, F. J., Yebra, M., Bermejo, I., Palacios-Alonso, M. A., Calleja, M. A., Luque, M., & Pérez‐Martín, J. (2017) · Medical Decision Making · doi:10.1177/0272989x16685088 · Cited by 12

A cost‐utility analysis comparing CT surveillance, PET‐CT surveillance, and planned postradiation neck dissection for advanced nodal HPV‐positive oropharyngeal cancer

Fu, T. S., Scheffler, P., Forner, D. W. A., Noel, C. W., Huang, S. H., Gilbert, R. W., Goldstein, D. P., O’Sullivan, B., Mehanna, H. M., Waldron, J. N., et al. (2021) · Cancer · doi:10.1002/cncr.33653 · Cited by 11

Impact of increasing treatment rates on cost-effectiveness of subcutaneous immunotherapy (SCIT) in respiratory allergy: a decision analytic modelling approach

Richter, A.-K., Klimek, L., Merk, H. F., Mülleneisen, N. K., Renz, H. E., Wehrmann, W., Werfel, T., Hamelmann, E. H., Siebert, U., Sroczynski, G., et al. (2018) · The European Journal of Health Economics · doi:10.1007/s10198-018-0970-6 · Cited by 11

Cost-effectiveness of adding Endocuff® to standard colonoscopies for interval colorectal cancer screening

Yu, T. M., Tradonsky, A., Tang, J., & Arnold, R. J. G. (2019) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s201328 · Cited by 10

Cost-effectiveness of twice-daily indacaterol/glycopyrrolate inhalation powder for the treatment of moderate to severe COPD in the US

Rajagopalan, K., Bloudek, L. M., Marvel, J., Dembek, C., & Kavati, A. (2018) · International Journal of COPD · doi:10.2147/copd.s177097 · Cited by 10

Decision-Analytic Modeling Studies in Prevention and Treatment of Iodine Deficiency and Thyroid Disorders: A Systematic Overview

Rochau, U., Qerimi, V., Schaffner, M., Schönhensch, M., Stojkov, I., Jahn, B., Hubalewska–Dydejczyk, A., Erlund, I., Thuesen, B. H., Zimmermann, M. B., et al. (2020) · Thyroid · doi:10.1089/thy.2018.0776 · Cited by 10

Cost‐effectiveness of the triple procedure – phacovitrectomy with posterior capsulotomy compared to phacovitrectomy and sequential procedures

Hertzberg, S. N. W., Veiby, N., Bragadóttir, R., Eriksen, K., Moe, M. C., Petrovski, B. É., & Petrovski, G. (2020) · Acta Ophthalmologica · doi:10.1111/aos.14367 · Cited by 10

A comparison between on-demand usage of rFVIIa vs prophylaxis use of emicizumab in high titer inhibitory hemophilia A patients in Iran

Saiyarsarai, P., Derakhshan, A. R., Khedmati, J., Eshghi, P., & Seyedifar, M. (2021) · Medicine · doi:10.1097/md.0000000000027303 · Cited by 10

Cost-Utility Analysis of Sacroiliac Joint Fusion in High-Risk Patients Undergoing Multi-Level Lumbar Fusion to the Sacrum

Ackerman, S. J., Deol, G. S., & Polly, D. W. (2022) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s377132 · Cited by 10

Exploring the Potential Cost-Effectiveness of Patient Decision Aids for Use in Adults with Obstructive Sleep Apnea

Trenaman, L., Sadatsafavi, M., Almeida, F. R., Ayas, N., Lynd, L. D., Marra, C. A., Stacey, D., & Bansback, N. J. (2014) · Medical Decision Making · doi:10.1177/0272989x14556676 · Cited by 10

Cost effectiveness of ixekizumab versus secukinumab in the treatment of moderate-to-severe plaque psoriasis in Spain

Johansson, E., Núñez, M., Svedbom, A., Dilla, T., & Hartz, S. (2018) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s167727 · Cited by 10

Applied Methods for Estimating Transition Probabilities from Electronic Health Record Data

Rodriguez, P. J., Ward, Z. J., Long, M. W., Austin, S. B., & Wright, D. R. (2021) · Medical Decision Making · doi:10.1177/0272989x20985752 · Cited by 10

Adding Events to a Markov Model Using DICE Simulation

Jaime, J., & Möller, J. (2017) · Medical Decision Making · doi:10.1177/0272989x17715636 · Cited by 9

US Tobacco 21 Policies and Potential Mortality Reductions by State

Tam, J., Crippen, A., Friedman, A. S., Jeon, J., Colston, D. C., Fleischer, N. L., Woude, C. A. V., Boelter, M. A., Holford, T. R., Levy, D. T., et al. (2024) · JAMA Health Forum · doi:10.1001/jamahealthforum.2024.4445 · Cited by 9

Oncotyrol – Center for Personalized Cancer Medicine: Methods and Applications of Health Technology Assessment and Outcomes Research

Siebert, U., Jahn, B., Rochau, U., Schnell‐Inderst, P., Kisser, A., Hunger, T., Sroczynski, G., Mühlberger, N., Willenbacher, W., Schnaiter, S., et al. (2015) · Zeitschrift für Evidenz Fortbildung und Qualität im Gesundheitswesen · doi:10.1016/j.zefq.2015.06.012 · Cited by 9

Systematic Assessment of Decision-Analytic Models for Chronic Myeloid Leukemia

Rochau, U., Schwarzer, R., Jahn, B., Sroczynski, G., Kluibenschaedl, M., Wolf, D. G. F., Radich, J. P., Brixner, D. I., Gastl, G. A., & Siebert, U. (2014) · Applied Health Economics and Health Policy · doi:10.1007/s40258-013-0071-8 · Cited by 9

Decision Modeling for Economic Evaluation in Otolaryngology–Head and Neck Surgery: Review of Techniques

Forner, D. W. A., Hoit, G., Noel, C. W., Eskander, A. E., de Almeida, J. R., Rigby, M. H., & Naimark, D. M. J. (2020) · Otolaryngology · doi:10.1177/0194599820957288 · Cited by 9

A Systematic Review of Modeling Approaches to Evaluate Treatments for Relapsed Refractory Multiple Myeloma: Critical Review and Considerations for Future Health Economic Models

Freitag, A. P., Sarri, G., Ta, A., Gurskyte, L., Cherepanov, D., & Hernandez, L. G. (2024) · PharmacoEconomics · doi:10.1007/s40273-024-01399-3 · Cited by 8

Evaluating the effects of a risk-adapted screening program for familial colorectal cancer in individuals between 25 and 50 years of age: study protocol for the prospective population-based intervention study FARKOR

Hoffmann, S., Crispin, A., Lindoerfer, D., Sroczynski, G., Siebert, U., & Mansmann, U. (2020) · BMC Gastroenterology · doi:10.1186/s12876-020-01247-6 · Cited by 8

Comparison of static and dynamic models of maternal immunization to prevent infant pertussis in Brazil

Russell, L. B., Kim, S., Toscano, C. M., Cosgriff, B., Minamisava, R., Andrade, A. L., Sanderson, C. F. B., & Sinha, A. (2020) · Vaccine · doi:10.1016/j.vaccine.2020.09.006 · Cited by 8

Inclusion of Additional Unintended Consequences in Economic Evaluation: A Systematic Review of Immunization and Tuberculosis Cost-Effectiveness Analyses

Nymark, L. S., Miller, A., & Vassall, A. (2021) · PharmacoEconomics - Open · doi:10.1007/s41669-021-00269-4 · Cited by 8

The long‐term impact and value of curative therapy for HIV: a modelling analysis

Guzauskas, G. F., & Hallett, T. B. (2023) · Journal of the International AIDS Society · doi:10.1002/jia2.26170 · Cited by 8

Cost effectiveness of interventions to improve adherence to statin therapy in ASCVD patients in the United States

Armstrong, S. O., & Little, R. A. (2019) · Patient Preference and Adherence · doi:10.2147/ppa.s213258 · Cited by 7

Comparing Decisions for Malaria Testing and Presumptive Treatment

Basu, S., Modrek, S., & Bendavid, E. (2014) · Medical Decision Making · doi:10.1177/0272989x14533609 · Cited by 7

Response to “The Life Table Method of Half-Cycle Correction: Getting It Right”

Naimark, D. M. J., Kabboul, N. N., & Krahn, M. D. (2014) · Medical Decision Making · doi:10.1177/0272989x14520719 · Cited by 7

Development of an Empirically Calibrated Model of Esophageal Squamous Cell Carcinoma in High-Risk Regions

Wang, Z., Zhang, Q., & Wu, B. (2019) · BioMed Research International · doi:10.1155/2019/2741598 · Cited by 7

Costs and benefits of interventions aimed at major infectious disease threats: lessons from the literature

Kellerborg, K., Brouwer, W. B. F., & van Baal, P. H. M. (2020) · The European Journal of Health Economics · doi:10.1007/s10198-020-01218-4 · Cited by 7

Modeling Early Warning Systems: Construction and Validation of a Discrete Event Simulation Model for Heart Failure

de Almeida, F. A., Ramos, I. C., Mölken, M. R., & Al, M. (2021) · Value in Health · doi:10.1016/j.jval.2021.04.004 · Cited by 7

Cost-Utility of Rhegmatogenous Retinal Detachment Repair With Pars Plana Vitrectomy, Scleral Buckle, and Pneumatic Retinopexy: A Microsimulation Model

Felfeli, T., Teja, B. J., Miranda, R. N., Simbulan, F., Sridhar, J. S., Sander, B., & Naimark, D. M. J. (2023) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2023.06.002 · Cited by 7

A State Transition Approach to Conceptualising Research: the Project Portfolio Management Domain

McDonald, C., & Sarbazhosseini, H. (2013) · Journal of the Association for Information Systems · Cited by 7

Changing Cycle Lengths in State-Transition Models: Doing it the Right Way

Chhatwal, J., Jayasuriya, S., & Elbasha, E. H. (2014) · Cited by 7

Characterizing Heterogeneity Bias in Cohort-Based Models

Elbasha, E. H., & Chhatwal, J. (2015) · PharmacoEconomics · doi:10.1007/s40273-015-0273-z · Cited by 7

Systematic Review of Economic Evaluations of Cycling Versus Swapping Medications in Patients With Rheumatoid Arthritis After Failure to Respond to Tumor Necrosis Factor Inhibitors

Matusevich, A. R. K., Suarez-Almazor, M. E., Cantor, S. B., Lal, L. S., Swint, J. M., & Lopez-Olivo, M. A. (2019) · Arthritis Care & Research · doi:10.1002/acr.23859 · Cited by 7

Incorporating healthcare access and equity in economic evaluations: a scoping review of guidelines

Dawkins, B., Shinkins, B., Ensor, T., Jayne, D. G., & Meads, D. M. (2024) · International Journal of Technology Assessment in Health Care · doi:10.1017/s0266462324000618 · Cited by 8

A Systematic Review of the Quality of Economic Models Comparing Thrombosis Inhibitors in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention

Hatz, M. H. M., Leidl, R., Yates, N., & Stollenwerk, B. (2014) · PharmacoEconomics · doi:10.1007/s40273-013-0128-4 · Cited by 6

Longitudinal Education and Career Outcomes of a Cancer Research Training Program for Underrepresented Students: The Meharry-Vanderbilt-Tennessee State University Cancer Partnership

Meadows, M. L., Suiter, S. V., Sealy, L. J., Marshall, D. R., Whalen, M. M., & Adunyah, S. E. (2022) · CBE—Life Sciences Education · doi:10.1187/cbe.21-10-0308 · Cited by 6

Multistate Modeling of Clinical Trajectories and Outcomes in the ICU: A Proof-of-Concept Evaluation of Acute Kidney Injury Among Critically Ill Patients With COVID-19

Lyons, P. G., Mody, A., Bewley, A. F., Schoer, M. B., Raju, B. N., Geng, E. H., Payne, P., Sinha, P., & Vijayan, A. (2022) · Critical Care Explorations · doi:10.1097/cce.0000000000000784 · Cited by 6

Cost-Effectiveness of 9-Valent HPV Vaccination for Patients Treated for High-Grade Cervical Intraepithelial Neoplasia in the UK

Cherif, A., Ovcinnikova, O., Palmer, C., Engelbrecht, K., Reuschenbach, M., & Daniels, V. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.37703 · Cited by 6

Systematic assessment of decision-analytic models evaluating diagnostic tests for acute myocardial infarction based on cardiac troponin assays

Veličković, V. M., Rochau, U., Conrads-Frank, A., Kee, F., Blankenberg, S., & Siebert, U. (2018) · Expert review of pharmacoeconomics & outcomes research · doi:10.1080/14737167.2018.1512857 · Cited by 5

Occupational Segregation And Hypertension Inequity: The Implication Of The Inverse Hazard Law Among Healthcare Workers

Chantarat, T., Enns, E. A., Hardeman, R. R., McGovern, P. M., Myers, S. L., & Dill, J. (2022) · Journal of Economics Race and Policy · doi:10.1007/s41996-022-00098-5 · Cited by 6

Health Economic Aspects of Childhood Excess Weight: A Structured Review

Onyimadu, O., Violato, M., Astbury, N. M., Jebb, S. A., & Petrou, S. (2022) · Children · doi:10.3390/children9040461 · Cited by 6

Cost-Effectiveness and Value-of-Information Analysis Using Machine Learning–Based Metamodeling: A Case of Hepatitis C Treatment

McCandlish, J. A., Ayer, T., & Chhatwal, J. (2022) · Medical Decision Making · doi:10.1177/0272989x221125418 · Cited by 6

Cost-effectiveness analysis of apixaban compared to low-molecularweight heparins and vitamin k antagonists for treatment and secondary prevention of venous thromboembolism.

Elías, I., Oyagüez, I., Alvarez-Sala, L. A., Garcia-Bragado, F., Navarro‐Ruiz, A., González, P., de Andrés-Nogales, F., & Soto, J. (2016) · PubMed · doi:10.7399/fh.2016.40.3.10461 · Cited by 6

Cost-Utility of Partially Implantable Active Middle Ear Implants for Sensorineural Hearing Loss: A Decision Analysis.

Kließ, M. K., Kluibenschaedl, M., Zoehrer, R., Schlick, B., Scandurra, F., & Urban, M. (2017) · Value in Health · doi:10.1016/j.jval.2017.04.020 · Cited by 5

Cost-utility of ticagrelor plus aspirin in diabetic patients with stable coronary artery disease

Wu, B. Y., & Shi, L. (2020) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaa082 · Cited by 6

A comprehensive framework for considering additional unintended consequences in economic evaluation

Nymark, L. S., & Vassall, A. (2020) · Cost Effectiveness and Resource Allocation · doi:10.1186/s12962-020-00218-8 · Cited by 6

Digitalization as an Engine for Change? Building a Vision Pathway towards a Sustainable Health Care System by Using the MLP and Health Economic Decision Modelling

Leväsluoto, J., Köhl, J., Sigfrids, A., Pihlajamäki, J., & Martikainen, J. A. (2021) · Sustainability · doi:10.3390/su132313007 · Cited by 6

A Tutorial on Time-Dependent Cohort State-Transition Models in R Using a Cost-Effectiveness Analysis Example

Alarid-Escudero, F., Krijkamp, E., Enns, E. A., Yang, A., Hunink, M. G. M., Pechlivanoglou, P., & Jalal, H. (2023) · Medical Decision Making · doi:10.1177/0272989x221121747 · Cited by 5

Developing a fall prevention intervention economic model

Saunders, H., Anderson, C. L., Feldman, F., Holroyd-Leduc, J. M., Jain, R., Liu, B., Macaulay, S., Marr, S., Silvius, J. L., Weldon, J., et al. (2023) · PLoS ONE · doi:10.1371/journal.pone.0280572 · Cited by 5

A Latent Class Approach to Modeling Trajectories of Health Care Cost in Pediatric Cystic Fibrosis

Levy, J. F., & Rosenberg, M. A. (2019) · Medical Decision Making · doi:10.1177/0272989x19859875 · Cited by 5

An All‐Suture–Based Technique for Meniscal Repair Is Cost‐Effective in Comparison to Partial Meniscectomy for Horizontal Cleavage Tears

Sherman, S. L., Askew, N., Nherera, L. M., Searle, R. J., & Flanigan, D. C. (2024) · Arthroscopy Sports Medicine and Rehabilitation · doi:10.1016/j.asmr.2023.100847 · Cited by 5

Cost-utility analysis of genetic polymorphism universal screening in colorectal cancer prevention by detection of high-risk individuals

Pereira, C., Areia, M., & Dinis-Ribeiro, M. J. (2019) · Digestive and Liver Disease · doi:10.1016/j.dld.2019.07.012 · Cited by 6

Cohort State-Transition Models in R: A Tutorial

Alarid‐Escudero, F., Krijkamp, E., Enns, E. A., Yang, A., Hunink, M. G. M., Pechlivanoglou, P., & Jalal, H. J. (2020)

An Introductory Tutorial on Cohort State-Transition Models in R Using a Cost-Effectiveness Analysis Example

Alarid-Escudero, F., Krijkamp, E., Enns, E. A., Yang, A., Hunink, M. G. M., Pechlivanoglou, P., & Jalal, H. (2023) · Medical Decision Making · doi:10.1177/0272989x221103163 · Cited by 39

Changing Cycle Lengths in State-Transition Models: Doing it the Right Way

Chhatwal, J., Jayasuriya, S., & Elbasha, E. H. (2014) · Cited by 7

Modeling Medical Decisions

Beck, J. R. (2016) · Springer eBooks · doi:10.1007/978-1-4939-3486-7_3

EE562 Is Less More? Aggregating Health States in State Transition Models

Ettinger, J., & Maervoet, J. (2025) · Value in Health · doi:10.1016/j.jval.2025.09.944